Semaglutide, a key component of both Ozempic and Wegovy, is a GLP-1 receptor agonist that plays a vital role in regulating insulin secretion and appetite, which are essential for managing type 2 diabetes and supporting weight loss efforts
Starting with a lower dose and gradually increasing helps minimize discomfort
This doesn't mean semaglutide isn't working
A comprehensive medication review ensures coordinated care and optimal safety monitoring
For GLP-1 receptor agonists, which suppress appetite centrally and slow gastric emptying, regulators want assurance that reduced caloric intake during critical growth windows does not compromise height velocity or bone density
A notable research effort, known as the STEP (Semaglutide GLP-1 Treatment Effect in People with Obesity) trial, revealed that participants taking Semaglutide GLP-1 achieved an average weight reduction of around 15% of their starting body weight within 68 weeks, unlike those taking a placebo